Stephen Davis (Australia)
Melbourne Brain Centre at The Royal Melbourne Hospital
Neurology
Professor Stephen Davis is the Professor of Translational Neuroscience at the University of Melbourne, Director of the Melbourne Brain Centre at the Royal Melbourne Hospital and a Past-President of the World Stroke Organization. He co-chairs the Australian Stroke Alliance, the Melbourne Mobile Stroke Unit program and the Australian Chinese Training Initiative of Neurology. He is a Past-President of the Australian and New Zealand Association of Neurologists and the Stroke Society of Australasia. He has received numerous awards including the 2011 William Feinberg Award from the American Stroke Association, the Bethlehem Griffiths Foundation Research Medal in 2011, the 2012 E Graeme Robertson award of the Australian and New Zealand Association of Neurologists, the 2012 Karolinska Award and the 2014 JJ Wepfer Award from the European Stroke Council, 2018 Stroke Leadership Award from the World Stroke Organization and the 2019 Chinese Stroke Association International Cooperation Award. He was elected as an inaugural Fellow in the Australian Academy of Health and Medical Sciences in 2015 and was the 2017 C Miller Fisher Visiting Professor at the Massachusetts General Hospital/Harvard. In 2021 he was appointed an Officer of the Order of Australia. His research is focused on acute therapy for both ischemic stroke and intracerebral haemorrhage, particularly the use of advanced imaging in selection of therapy. He is a consulting editor for Stroke and serves on editorial boards of the International Journal of Stroke, the European Stroke Journal and the Journal of Clinical Neuroscience. He is the Principal Investigator of an NHMRC stroke program grant 2017-2021 and a MRFF grant on use of tranexamic acid in the mobile stroke unit for intracerebral hemorrhage. He is the Co-Lead (with G Donnan) of the 2021 Frontiers MRFF grant on Pre-Hospital Stroke Care. He has an h-index of 100, has co-authored three books, numerous book chapters, and more than 550 peer-reviewed research papers.

Presenter of 1 Presentation

 Conference Calendar

Prehospital Strategies for Brain Hemorrhage Management

Session Name
0520 - Prehospital Stroke Care (ID 39)
Session Type
Plenary Session
Date
28.10.2021, Thursday
Session Time
19:15 - 20:45
Room
PLENARY
Presenter
Lecture Time
19:57 - 20:11

Abstract

Abstract Body

Mobile stroke units (MSUs) substantially reduce reperfusion therapy times in acute ischemic stroke (AIS). Phase III trials in the USA and Europe have shown that they improve clinical outcomes, compared with standard of care in emergency departments. MSUs are also an ideal platform for treatment of intracerebral hemorrhage (ICH). The Melbourne MSU has been operational since 2017. In a final diagnosis of stroke, approximately 15% of our cases have intracranial hemorrhages, predominantly ICH, smaller numbers of subarachnoid, subdural and extradural hemorrhages. Around 50% were treated with intravenous anti-hypertensive treatment. Patients were bypassed to a comprehensive stroke centre from the MSU in about one third of cases. Compared to patients with MSU-AIS, patients with ICH had faster onset to emergency call and onset to scene arrival times. We are conducting the STOP-MSU trial which is randomizing patients to tranexamic acid (TXA) versus placebo within 2 hours of the onset of ICH, testing the hypothesis that TXA will reduce ICH growth at 24 hours. This ongoing trial has recruited over 100 patients, about a third from the Melbourne MSU and the remainder from emergency departments in Australia, New Zealand, Taiwan, Vietnam and Finland. MSUs can facilitate ultra-early ICH diagnosis, treatment and triage.

Hide